" alt="Gilead licenses HIV-prevention drug to generic drugmakers" width="2560" height="1715" data-lazy-srcset="https://business.inquirer.net/files/2024/10/Gilead-Sciences-headquarters-FILE-scaled.jpg 2560w, https://business.inquirer.net/files/2024/1

The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North Africa to make and sell at a lower price its groundbreaking drug lenacapavirredgaming, a twice-yearly injection that provides